Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAPDH | P04406 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16667 | 1.00 | GAPDH (0.38) | GAPDHPTPN11CMKLR1PTGS1AKR1C3 | |
| Phosphoric Acid SCHEMBL21408816 | 0.92 | GRIN2D (0.34) | GAPDHPTPN11 | |
| SCHEMBL8426286 | 0.92 | GAPDH (0.33) | GAPDHPTPN11 | |
| SCHEMBL10753894 | 0.90 | GAPDH (0.32) | GAPDHPTPN11 | |
| SCHEMBL9781496 | 0.90 | GRIK1 (0.34) | GAPDHPTPN11 | |
| SCHEMBL7713662 | 0.90 | HDAC1 (0.35) | GAPDHPTPN11CMKLR1FFAR3HDAC3 | |
| SCHEMBL23036469 | 0.85 | — | — | |
| Malic Acid SCHEMBL14740589 | 0.85 | SMN1; SMN2 (0.52) | — | |
| SCHEMBL1784421 | 0.83 | GAPDH (0.39) | GAPDH | |
| SCHEMBL1784419 | 0.83 | GAPDH (0.39) | GAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318473-A1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | ABRAXIS BIOSCIENCE LLC (US) | 2018-11-08 | — | — | US | claimed |
| EP-3345632-A1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | Abraxis BioScience, LLC (US) | 2018-07-11 | — | — | EP | claimed |
| EP-3345631-A1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | Abraxis BioScience, LLC (US) | 2018-07-11 | — | — | EP | claimed |
| US-9954126-B2 | Three-dimensional photovoltaic devices including cavity-containing cores and methods of manufacture | Q1 NANOSYSTEMS CORPORATION (US) | 2018-04-24 | — | — | US | claimed |
| EP-1861070-B1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | ABRAXIS BIOSCIENCE LLC (US) | 2018-01-17 | — | — | EP | claimed |
| US-20170203012-A1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | ABRAXIS BIOSCIENCE LLC (US) | 2017-07-20 | — | — | US | claimed |
| US-20160043251-A1 | Three-Dimensional Photovoltaic Devices Including Cavity-containing Cores and Methods of Manufacture | ACADIA WOODS PARTNERS, LLC | 2016-02-11 | — | — | US | claimed |
| US-20160043253-A1 | Methods for Manufacturing Three-Dimensional Metamaterial Devices with Photovoltaic Bristles | ACADIA WOODS PARTNERS, LLC | 2016-02-11 | — | — | US | claimed |
| EP-2896412-A1 | Drugs with improved hydrophobicity for incorporation in medical devices | Abraxis BioScience, LLC (US) | 2015-07-22 | — | — | EP | claimed |
| US-20150190556-A1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | ABRAXIS BIOSCIENCE LLC (US) | 2015-07-09 | — | — | US | claimed |
| WO-2006020742-A2 | MEDICAL DEVICES HAVING NANOPOROUS LAYERS AND METHODS FOR MAKING THE SAME | SETAGON, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20050137684-A1 | Stent with therapeutically active drug coated thereon | PFIZER INC | 2005-06-23 | — | — | US | claimed |
| US-20050085902-A1 | Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures,Including delivery using a modified stent | CARDINAL HEALTH SWITZERLAND 515 GmbH (CH) | 2005-04-21 | — | — | US | claimed |
| EP-1407726-A1 | Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent | Cordis Corporation (US) | 2004-04-14 | — | — | EP | claimed |
| US-6585764-B2 | Stent with therapeutically active dosage of rapamycin coated thereon | CORDIS CORPORATION | 2003-07-01 | — | — | US | claimed |
| EP-0587565-B1 | INTRAOCULAR LENS WITH HAPTIC ANCHOR PLATE | MEDEVEC LICENSING BV (NL) | 1998-08-19 | — | — | EP | claimed |
| EP-0587565-A4 | INTRAOCULAR LENS WITH HAPTIC ANCHOR PLATE. | CUMMING STUART J (US) | 1995-02-22 | — | — | EP | claimed |
| EP-0587565-A1 | INTRAOCULAR LENS WITH HAPTIC ANCHOR PLATE | MEDEVEC LICENSING B.V. (NL) | 1994-03-23 | — | — | EP | claimed |
| WO-1992021304-A1 | INTRAOCULAR LENS WITH HAPTIC ANCHOR PLATE | CUMMING STUART J (US) | 1992-12-10 | — | — | WO | claimed |
| US-5047051-A | Intraocular lens with haptic anchor plate | THE NICE TRUST, A TRUST OF THE ISLE OF MAN | 1991-09-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170203012-A1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | MIF, MKI67, ABCB11 | GAPDH 3259/4885PTPN11 3307/4885CMKLR1 876/4885 |
| US-20180318473-A1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | MIF, MKI67, ABCB11 | GAPDH 3259/4885PTPN11 3307/4885CMKLR1 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.